(Q40615827)

22 September 2017

Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders (English)

1 reference

22 September 2017

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

3 April 2024

author name string

Elizabeth A. Thomas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623496

3 April 2024

Roshni C. George

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623496

3 April 2024

J. Gregor Sutcliffe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14623496

3 April 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14623496

3 April 2024

publication date

1 December 2003

1 reference

full work available at URL

22 September 2017

https://api.elsevier.com/content/article/PII:S0952327803001662?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

https://api.elsevier.com/content/article/PII:S0952327803001662?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Prostaglandins, Leukotrienes and Essential Fatty Acids

3 April 2024

published in

1 reference

22 September 2017

69

1 reference

22 September 2017

421-427

1 reference

22 September 2017

6

1 reference

Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer’s disease

22 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Altered apolipoprotein D expression in the brain of patients with Alzheimer disease

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Apolipoprotein D in the aging brain and in Alzheimer's dementia

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder.

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus.

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion.

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Immunologic and steroid binding properties of the GCDFP-24 protein isolated from human breast gross cystic disease fluid

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Binding properties of progesterone-binding Cyst protein, PBCP

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Is apolipoprotein D a mammalian bilin-binding protein?

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

A human axillary odorant is carried by apolipoprotein D

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Arachidonic acid binds to apolipoprotein D: implications for the protein's function

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Increased concentrations of phosphatidylinositol (PI) and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases.

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects.

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Abnormal incorporation of arachidonic acid into platelets of drug-free patients with schizophrenia

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin

3 April 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Niacin skin flush in schizophrenia: a preliminary report

3 April 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

The growing phospholipase A2 superfamily of signal transduction enzymes

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

3 April 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.

3 April 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Analysis of human synovial fluid phospholipase A2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Measurement of protein using bicinchoninic acid

3 April 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Arachidonic acid mobilization in P388D1 macrophages is controlled by two distinct Ca(2+)-dependent phospholipase A2 enzymes

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Astrocytes synthesize and secrete the lipophilic ligand carrier apolipoprotein D

3 April 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

3 April 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

3 April 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding

3 April 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PLEFA.2003.08.014

3 April 2024

Identifiers

1 reference

22 September 2017

1 reference